Cat. No.: DIA-0231029
Product Information | |
---|---|
CAS No. | 1073612-91-5 |
Formula | C19H12F3NO3S2 |
Molecular Weight | 423.43 |
SMILES | OC(=O)C1=CC=C(C=C1)/C=C2/SC(=S)N(CC3=CC(=CC=C3)C(F)(F)F)C2=O |
Product Description | CY-09 is a specific NLRP3 inflammasome inhibitor that directly targeted NLRP3 itself。 It is tested against the five major cytochrome P450 enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 with half maximal inhibitory concentration (IC50) values of 18.9, 8.18, >50, >50, and 26.0 µM, respectively. |
Format & Storage | |
---|---|
Purity | > 97% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.